Modulating the Anticancer Activity of Ruthenium(II)-Arene Complexes.

Abstract

Following the identification of [Ru(η(6)-p-cymene)Cl2(1H,1H,2H,2H-perfluorodecyl-3-(pyridin-3-yl)propanoate)], a ruthenium(II)-arene complex with a perfluoroalkyl-modified ligand that displays remarkable in vitro cancer cell selectivity, a series of structurally related compounds were designed. In the new derivatives, the p-cymene ring and/or the chloride ligands are substituted by other ligands to modulate the steric bulk or aquation kinetics. The new compounds were evaluated in both in vitro (cytotoxicity and migration assays) and in vivo (chicken chorioallantoic membrane) models and were found to exhibit potent antivascular effects.

• Authors: Catherine M Clavel, Emilia Păunescu, Patrycja Nowak-Sliwinska, Arjan W Griffioen, Rosario Scopelliti, Paul J Dyson
• Journal: Journal of medicinal chemistry (J Med Chem) Vol. 58 Issue 8 Pg. 3356-65 (Apr 23 2015) ISSN: 1520-4804 [Electronic] United States
• PMID: 25812075 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Angiogenesis Inhibitors
• Antineoplastic Agents
• Coordination Complexes
• Cymenes
• Monoterpenes
• 4-cymene
• Ruthenium

Topics

• Angiogenesis Inhibitors (chemistry, pharmacology)
• Animals
• Antineoplastic Agents (chemistry, pharmacology)
• Cell Line, Tumor
• Cell Proliferation (drug effects)
• Chick Embryo
• Coordination Complexes (chemistry, pharmacology)
• Crystallography, X-Ray
• Cymenes
• Humans
• Models, Molecular
• Monoterpenes (chemistry, pharmacology)
• Neoplasms (drug therapy)
• Ruthenium (chemistry, pharmacology)